| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP1A2 |
| Uniprot No | P05177 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 2-516aa |
| 氨基酸序列 | ALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKNPHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDGQSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELMAGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFPILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGNLIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLSDRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPELWEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLEFSVPPGVKVDLTPIYGLTMKHARCEHVQARLRFSIN |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CYP1A2重组蛋白的3篇代表性文献摘要概括：
1. **《Heterologous expression of human cytochrome P450 1A2 in Escherichia coli: purification, characterization, and catalytic activity》**
- 作者：Guengerich, F.P., et al.
- 摘要：研究报道了人CYP1A2在大肠杆菌中的异源表达和纯化方法，分析了重组蛋白的酶活性，证实其可代谢典型底物(如菲那西汀和咖啡因)，并探讨了血红素插入对功能的影响。
2. **《Functional characterization of human cytochrome P450 1A2 in insect cells: comparison with recombinant enzyme expressed in E. coli》**
- 作者：Hanna, I.H., et al.
- 摘要：对比了昆虫细胞(杆状病毒系统)和大肠杆菌表达的CYP1A2重组蛋白，发现两者在底物代谢动力学(如茶碱氧化)和热稳定性方面存在差异，提示表达系统影响酶性质。
3. **《Structural basis of ligand binding to CYP1A2: insights from co-crystallization with inhibitors》**
- 作者：Sansen, S., et al.
- 摘要：通过重组CYP1A2与抑制剂(如α-萘黄酮)的共结晶，解析了其三维结构，揭示了活性位点的关键氨基酸残基与配体结合模式，为药物相互作用研究提供结构基础。
注：以上文献标题和作者为示例性概括，实际文献检索建议通过PubMed或SciFinder核实具体信息。
**Background on CYP1A2 Recombinant Protein**
Cytochrome P450 1A2 (CYP1A2) is a member of the cytochrome P450 enzyme superfamily, primarily expressed in the liver, where it plays a critical role in the metabolism of xenobiotics and endogenous compounds. This enzyme is involved in the oxidative breakdown of approximately 10-15% of clinically used drugs, including caffeine, clozapine, and theophylline, as well as environmental procarcinogens like heterocyclic amines and polycyclic aromatic hydrocarbons. Its activity is influenced by genetic polymorphisms, environmental factors (e.g., smoking), and drug interactions, leading to interindividual variability in drug response and toxicity risks.
Recombinant CYP1A2 protein is produced using biotechnological methods, often through heterologous expression in systems like *E. coli*, yeast, or insect cells. These systems enable large-scale production of the enzyme for *in vitro* studies, bypassing challenges associated with isolating it from human tissues. The recombinant protein retains catalytic activity, allowing researchers to study substrate specificity, inhibition kinetics, and metabolic pathways in controlled environments.
Research applications of recombinant CYP1A2 include drug development, toxicity screening, and mechanistic studies of enzyme induction or inhibition. For instance, it is used to assess drug-drug interactions, evaluate metabolite formation, and characterize genetic variants affecting enzyme function. Additionally, CYP1A2 is induced by aryl hydrocarbon receptor (AhR) agonists, such as dioxins, linking it to environmental toxicology studies.
Structural studies using recombinant CYP1A2 have provided insights into its active site architecture and substrate-binding mechanisms, facilitating the design of safer drugs and personalized therapies. Its role in activating procarcinogens also underscores its relevance in cancer research. Overall, recombinant CYP1A2 serves as a vital tool for advancing pharmacology, toxicology, and precision medicine.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
